Sign in

CIK 0002044725

  • Emerging growth company

Evommune, Inc.

Sign in to watch
Ticker
EVMN
Exchange
NYSE
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
850742575
Phone
+1 650-223-7745
Business address
1891 PAGE MILL RD, PALO ALTO, CA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-11-07 RA CAPITAL MANAGEMENT, L.P. Director Conversion +691,441 691,441
2025-11-07 RA CAPITAL MANAGEMENT, L.P. Director Purchase +1,157,096 $16.00 $18.5M 2,674,425
2025-11-07 RA CAPITAL MANAGEMENT, L.P. Director Purchase +92,904 $16.00 $1.5M 784,345
2025-11-07 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series C Preferred Stock −12,924,620 0
2025-11-07 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series C Preferred Stock −5,889,699 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion +1,441,032 1,441,032
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion +1,632,441 1,632,441
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion +294,502 294,502
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series Seed Preferred Stock −7,145,647 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series Seed Preferred Stock −3,572,816 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series A Preferred Stock −2,582,243 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series A Preferred Stock −7,230,283 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series B Preferred Stock −1,895,260 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series B Preferred Stock −2,104,740 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series C Preferred Stock −313,571 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series C Preferred Stock −313,571 0
2025-11-07 Pivotal bioVenture Partners Fund I, L.P. Director Conversion · Series C Preferred Stock −2,508,575 0
2025-11-05 Patel Jeegar Pravinkumar Chief Scientific Officer Grant or award · Employee Stock Option (Right to Buy) +179,619 179,619
2025-11-05 Drew Janice Suzann EVP, Operations Grant or award · Employee Stock Option (Right to Buy) +231,274 231,274
2025-11-05 Carver Kyle Chief Financial Officer Grant or award · Employee Stock Option (Right to Buy) +279,408 279,408

Page 7 of 8 · 145 trades